Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River's specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r.

Business Wire • Oct 13, 2026

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.

Business Wire • Oct 9, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally?

CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.

Zacks Investment Research • Oct 7, 2026

PGNY or CRL: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Oct 7, 2026

Charles River and Autolomous Partner to Transform Laboratory Execution Systems

WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches.

Business Wire • Oct 6, 2026

Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan

Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth.

MarketBeat • Sep 26, 2026

Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript

Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript

Seeking Alpha • Sep 24, 2026

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day.

Business Wire • Sep 24, 2026

Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday

U.S. stocks were lower, with the Nasdaq Composite falling over 150 points on Thursday.

Benzinga • Sep 24, 2026

PGNY vs. CRL: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Sep 18, 2026